We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Malignant neoplasms of ill-defined, secondary and unspecified sitesMalignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Childhood and adolescent cancers comprise a heterogeneous group of rare diseases, mostly distinct to those diagnosed in adults. Survival of children and adolescents with cancer has considerably improved in recent decades, but cancer remains the most common cause of disease-related mortality in developed countries. In the case of disease relapse, the prognosis for paediatric patients is poor with survival rates of < 20%.
Better understanding of tumor biology has led to exponentially increased development of novel targeted therapies and immunotherapies in the last two decades. Several molecularly targeted medicines have shown significant activity in specific pediatric cancers in the presence of matching alterations. However, very few have been approved for the treatment of paediatric cancers.
Many children and young adults are currently receiving targeted therapies (usually in the setting of relapse) outside of formal clinical trials, often on a compassionate basis (given freely by the drug company) or "off-label" (paid for but with no license/marketing authorisation for that indication). Data is not routinely collected on the safety and activity of these medications.
The goal of the SACHA international project is to collect real world data on patients being treated with these medications with a particular emphasis on safety and activity. The aim is to share this information so that drugs with poor side effects or low activity levels are not used unnecessarily.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Patient receiving innovative therapy within a clinical trial Refusal to consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by BIRMINGHAM WOMEN'S AND CHILDREN'S NHS FOUNDATION TRUST and funded by European Science Foundation .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 55822
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
